Fortress Biotech (FBIO) Free Cash Flow (2010 - 2025)
Fortress Biotech (FBIO) posted quarterly Free Cash Flow of -$12.5 million for Q4 2025, up 2.81% year-over-year from -$12.2 million in Q4 2024, and down 105.3% quarter-over-quarter from -$6.1 million in Q3 2025.
Powered by 
Analysis
Fortress Biotech (FBIO) Free Cash Flow (2010 - 2025) Analysis & Trends
Fortress Biotech's Free Cash Flow history runs 16 years deep, the most recent figure standing at -$12.5 million for Q4 2025.
- In Q4 2025, Free Cash Flow rose 2.81% year-over-year to -$12.5 million; the TTM figure through Dec 2025 stood at -$65.8 million (up 17.97% YoY), while the FY2025 annual figure was -$65.8 million, up 17.97% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$12.5 million, down from -$6.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$6.1 million in Q3 2025, with the low at -$50.5 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$26.5 million (2024), against an average of -$28.9 million.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow slumped 116.78% in 2022, then surged 67.26% in 2025.
- Fortress Biotech's Free Cash Flow stood at -$40.7 million in 2021, then fell by 24.32% to -$50.5 million in 2022, then jumped by 30.82% to -$35.0 million in 2023, then surged by 63.08% to -$12.9 million in 2024, then increased by 2.81% to -$12.5 million in 2025.
- Business Quant data shows FBIO's Free Cash Flow at -$12.5 million in Q4 2025, -$6.1 million in Q3 2025, and -$27.6 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -12.54 Mn |
| Sep 30, 2025 | -6.11 Mn |
| Jun 30, 2025 | -27.56 Mn |
| Mar 31, 2025 | -19.56 Mn |
| Dec 31, 2024 | -12.91 Mn |
| Sep 30, 2024 | -18.66 Mn |
| Jun 30, 2024 | -23.23 Mn |
| Mar 31, 2024 | -25.39 Mn |
| Dec 31, 2023 | -34.96 Mn |
| Sep 30, 2023 | -16.78 Mn |
| Jun 30, 2023 | -33.31 Mn |
| Mar 31, 2023 | -43.24 Mn |
| Dec 31, 2022 | -47.94 Mn |
| Sep 30, 2022 | -44.25 Mn |
| Jun 30, 2022 | -41.73 Mn |
| Mar 31, 2022 | -48.20 Mn |
| Dec 31, 2021 | -40.65 Mn |
| Sep 30, 2021 | -22.16 Mn |
| Jun 30, 2021 | -36.06 Mn |
| Mar 31, 2021 | -22.23 Mn |